Exponent バランスシートの健全性
財務の健全性 基準チェック /66
Exponentの総株主資本は$338.3M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$687.4Mと$349.0Mです。 Exponentの EBIT は$116.7Mで、利息カバレッジ比率-14です。現金および短期投資は$118.6Mです。
主要情報
0%
負債資本比率
US$0
負債
| インタレスト・カバレッジ・レシオ | -14x |
| 現金 | US$118.55m |
| エクイティ | US$338.34m |
| 負債合計 | US$349.04m |
| 総資産 | US$687.38m |
財務の健全性に関する最新情報
Recent updates
EXPO: Resilient End Markets And Buybacks Will Support Future Earnings Quality
Analysts have reduced their price target on Exponent to $80 from $95, citing a preference for stocks with more resilient end markets and clearer growth drivers in the current small-cap industrials group. Analyst Commentary Recent research highlights that while the price target on Exponent has been adjusted to US$80 from US$95, the stock still sits on the preferred list within the smaller cap industrials group.EXPO: Buybacks And Resilient End Markets Will Support Future Earnings Quality
Analysts have trimmed their fair value estimate for Exponent to $90 from $95, reflecting lower price targets in recent research and a stronger emphasis on selectivity in smaller cap industrials. Analyst Commentary Recent research points to a more selective stance on smaller cap industrials, with Exponent still viewed as a quality exposure for investors who prioritize resilient demand and clear growth drivers.Exponent: Rising Demand And A Reasonable Valuation Make It A Buy
Summary Exponent is a market leader in scientific and engineering consulting, boasting a 13-year dividend growth streak and a fortress balance sheet. EXPO’s fiscal 2026 outlook signals rising top and bottom lines, with AI-related demand driving proactive and reactive service growth. The stock trades at ~26.5x FY26E EPS, well below its 5-year average, suggesting undervaluation with a fair value estimate of $73.80 versus a ~$65 share price. Dividend safety is outstanding, supported by a conservative ~50% payout ratio, robust free cash flow, and no debt. Read the full article on Seeking AlphaEXPO: AI Failure Analysis And Buybacks Will Support Higher Earnings Quality
Analysts have adjusted their view on Exponent with a modest change to the price target in the $5 range, reflecting updated assumptions on growth, profitability and a slightly higher future P/E multiple informed by recent mixed revisions from JPMorgan and UBS. Analyst Commentary Recent commentary around Exponent highlights a mix of caution and optimism, with price targets adjusted within a narrow range and opinions split on the risk and reward at current levels.EXPO: AI Failure Analysis Demand Will Support Higher Earnings Quality
Analysts have adjusted the 12 month price target on Exponent to $95 from $90, reflecting updated assumptions around revenue growth, profit margins, and the P/E multiple they are willing to apply to future earnings. Analyst Commentary Recent Street research on Exponent has centered on how much investors are willing to pay for the company’s future earnings, with price targets adjusted as analysts revisit revenue assumptions, profit margins, and the P/E multiple.EXPO: AI Failure Analysis Work Will Sustain Premium P/E And Shareholder Returns
Analysts have trimmed their average price target for Exponent by $1.67 to reflect slightly lower fair value and profit margin assumptions, while still applying a relatively high future P/E multiple informed by recent mixed price target moves from JPMorgan and UBS. Analyst Commentary Recent Street research on Exponent reflects a mix of optimism about the business model and caution around valuation and near term execution, which is why price targets have moved in both directions.EXPO: AI Failure Analysis Work Will Support Margins And Shareholder Returns
Analysts have lifted their 12 month price target on Exponent by about $6 to around $92. This reflects updated expectations around revenue, margins and a slightly lower future P/E multiple following recent research updates from major firms.EXPO: Buybacks And Dividend Increases Will Support Future Shareholder Returns
Analysts nudged their price target on Exponent higher by $4, citing slightly firmer growth and margin assumptions, along with a modestly lower future P/E outlook as key supports for the revised view. Analyst Commentary Recent research coverage around Exponent has centered on how much investors should be willing to pay for the company relative to its growth and margin profile.EXPO: Raised UBS Target And Buybacks Will Support Higher Future P/E
Analysts have raised their price target on Exponent by $4 to $85, citing updated assumptions that include slightly lower revenue growth, a modestly higher discount rate, improved profit margin expectations, and a higher future P/E multiple. Analyst Commentary Recent Street research around Exponent highlights a mix of optimism and restraint, with the latest published work focusing on valuation inputs, growth expectations, and how much investors are willing to pay for the stock through the P/E multiple.Exponent (NASDAQ:EXPO) Is Increasing Its Dividend To $0.31
The board of Exponent, Inc. ( NASDAQ:EXPO ) has announced that the dividend on 20th of March will be increased to...EXPO: Bullish JPMorgan Initiation Will Support Confidence In Updated Fair Value Estimate
Analysts have raised their fair value estimate for Exponent from US$76.00 to US$81.00, citing updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple in light of recent bullish Street research. Analyst Commentary Recent Street research, including a new bullish view from JPMorgan, has put more attention on how Exponent is priced and what could get in the way of the updated fair value estimate of US$81.00.EXPO: AI Failure Analysis Work Will Offset Automation Headwind Risks
Analysts have trimmed their price target on Exponent to US$90 from US$100, citing both the potential for increased AI driven failure analysis work and the offsetting risk that greater automation could reduce billable hours in consulting. Analyst Commentary Recent research points to a more balanced view on Exponent, with the reduced US$90 price target reflecting both potential upside from AI driven work and execution risks around automation in core consulting practices.EXPO: AI Failure Analysis Demand Will Support Future Consulting Engagements
Analysts have reduced their fair value estimate for Exponent to $90 from $100, citing a lower assumed future P/E multiple as they weigh the potential for AI-driven demand for failure analysis work against the risk that automation could reduce billable hours across the consulting sector. Analyst Commentary Recent commentary from bullish analysts centers on how AI adoption could shape Exponent's long term opportunity set, even as they factor in the risk that automation may cap billable hours across the consulting sector.What Exponent, Inc.'s (NASDAQ:EXPO) P/E Is Not Telling You
Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 34.9x might make it look like a strong sell...EXPO: AI Failure Analysis Demand Will Outweigh Automation Efficiency Headwinds
Analysts have nudged their fair value estimate for Exponent higher to approximately $85.50 from $83.00 per share, citing the potential for AI driven demand in complex failure analysis work, while acknowledging that automation related efficiency gains could temper billable hours across the consulting industry. Analyst Commentary Bullish analysts highlight that the revised target still implies meaningful upside from current levels, even after a modest trim.EXPO: AI-Driven Demand Will Drive Future Engagements Despite Automation Headwinds
Analysts have revised Exponent's price target downward by $10 to $90 per share, citing potential opportunities from AI-driven engagements as well as industry headwinds related to automation efficiencies. Analyst Commentary Following the recent revision to Exponent's price target, analysts have highlighted both opportunities and risks facing the company in today's evolving market landscape.EXPO: AI-Driven Client Demand Will Offset Automation Concerns In Consulting
Exponent’s analyst price target has been reduced by $10 to $90, as analysts cite ongoing automation concerns that could impact the consulting sector. They also note potential opportunities from increased AI-driven client demand.Exponent, Inc. Just Beat EPS By 8.5%: Here's What Analysts Think Will Happen Next
A week ago, Exponent, Inc. ( NASDAQ:EXPO ) came out with a strong set of third-quarter numbers that could potentially...EXPO: Increased Buyback Will Drive Shareholder Returns In Coming Quarters
Narrative Update: Exponent Analyst Price Target Adjustment Analysts have lowered their price target for Exponent from $88 to $83. This change reflects updated expectations for revenue growth and profitability margins moving forward.Returns On Capital At Exponent (NASDAQ:EXPO) Have Stalled
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...A Look At The Fair Value Of Exponent, Inc. (NASDAQ:EXPO)
Key Insights Exponent's estimated fair value is US$63.97 based on 2 Stage Free Cash Flow to Equity Exponent's US$70.44...When Should You Buy Exponent, Inc. (NASDAQ:EXPO)?
Exponent, Inc. ( NASDAQ:EXPO ), might not be a large cap stock, but it received a lot of attention from a substantial...Exponent (NASDAQ:EXPO) Knows How To Allocate Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...Subdued Growth No Barrier To Exponent, Inc.'s (NASDAQ:EXPO) Price
Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 36.7x might make it look like a strong sell...Is Exponent, Inc. (NASDAQ:EXPO) Potentially Undervalued?
Exponent, Inc. ( NASDAQ:EXPO ), might not be a large cap stock, but it saw significant share price movement during...Return Trends At Exponent (NASDAQ:EXPO) Aren't Appealing
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Exponent: A Unique Dividend Contender That Is Valued At A Premium
Summary Exponent Inc. is a market leader in scientific and engineering consulting, with a 13-year dividend growth streak and a solid balance sheet. Despite strong revenue and earnings growth, the valuation is at a premium, making Exponent a hold. The company's competitive advantages include its reputation, technical expertise, and long-term client relationships, ensuring continued market leadership. Exponent's dividend safety is excellent, supported by a conservative payout ratio and robust free cash flow, but the current valuation is a concern. Read the full article on Seeking AlphaExponent's (NASDAQ:EXPO) Shareholders Will Receive A Bigger Dividend Than Last Year
Exponent, Inc.'s ( NASDAQ:EXPO ) dividend will be increasing from last year's payment of the same period to $0.30 on...Exponent, Inc.'s (NASDAQ:EXPO) Intrinsic Value Is Potentially 34% Above Its Share Price
Key Insights The projected fair value for Exponent is US$122 based on 2 Stage Free Cash Flow to Equity Exponent is...Risks To Shareholder Returns Are Elevated At These Prices For Exponent, Inc. (NASDAQ:EXPO)
Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 42.7x might make it look like a strong sell...Here's What To Make Of Exponent's (NASDAQ:EXPO) Decelerating Rates Of Return
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Exponent's (NASDAQ:EXPO) Earnings Seem To Be Promising
Despite posting healthy earnings, Exponent, Inc.'s ( NASDAQ:EXPO ) stock has been quite weak. Along with the solid...Estimating The Intrinsic Value Of Exponent, Inc. (NASDAQ:EXPO)
Key Insights Exponent's estimated fair value is US$114 based on 2 Stage Free Cash Flow to Equity Current share price of...Operational Efficiency And Tactical Investments Set To Propel Future Profitability And Revenue Growth
Exponent's strategic management and operational efficiency improvements are poised to enhance future profitability and earnings potential.Exponent, Inc.'s (NASDAQ:EXPO) Share Price Not Quite Adding Up
Exponent, Inc.'s ( NASDAQ:EXPO ) price-to-earnings (or "P/E") ratio of 51.1x might make it look like a strong sell...財務状況分析
短期負債: EXPOの 短期資産 ( $340.9M ) が 短期負債 ( $142.2M ) を超えています。
長期負債: EXPOの短期資産 ( $340.9M ) が 長期負債 ( $206.8M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: EXPOは負債がありません。
負債の削減: EXPO過去 5 年間負債を抱えていません。
債務返済能力: EXPOには負債がないため、営業キャッシュフロー でカバーする必要はありません。
インタレストカバレッジ: EXPOには負債がないため、利息支払い の負担は問題になりません。
貸借対照表
健全な企業の発掘
企業分析と財務データの現状
| データ | 最終更新日(UTC時間) |
|---|---|
| 企業分析 | 2026/06/12 17:21 |
| 終値 | 2026/06/12 00:00 |
| 収益 | 2026/04/03 |
| 年間収益 | 2026/01/02 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Exponent, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Joseph Foresi | Brean Capital Historical (Janney Montgomery) |
| Alexis Huseby | D.A. Davidson & Co. |
| Tomohiko Sano | J.P. Morgan |